Search results for "Heart failure"
Combat cardiac risks of cancer therapies
One challenge of treating cancer is preventing, diagnosing, and treating heart failure in at-risk patients, and figuring out which patients would benefit from intervention.
1 Sep 2018
Sacubitril-valsartan appears cost-effective in certain heart failure patients
Treatment value was highest in patients with class II heart failure, who also benefited most from treatment in the PARADIGM-HF trial, and improved outcomes with the drug would need to be sustained for at least 36 months to keep the cost per quality-adjusted life-year below a $100,000 threshold.
30 Aug 2016
CA-125-guided therapy may improve outcomes for acute heart failure vs. standard of care
A multicenter randomized trial compared postdischarge therapy in patients who were hospitalized for acute heart failure and had high CA-125 levels.
16 Aug 2016
AHA evaluates heart failure risks from prescription drugs, OTCs, alternative products
The scientific statement identifies prescription medications that may exacerbate underlying myocardial dysfunction, prescription drugs known to cause direct myocardial toxicity, and the sodium level of some over-the-counter medications, among other concerns.
19 Jul 2016
Guideline updated to include new drugs for stage C heart failure with reduced ejection fraction
Among other recommendations, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, or an angiotensin receptor-neprilysin inhibitor, along with a beta-blocker and an aldosterone antagonist, is the new recommended therapy to reduce morbidity and mortality in patients with chronic symptomatic heart failure with reduced ejection fraction.
24 May 2016
New trials provide data to improve medication management in hypertension
A U.K. study compared morning versus evening dosing of antihypertensive drugs, a U.S. study looked at optimal dosing in patients with proteinuria, and a trial in Spain tested self-titration in patients with poorly controlled hypertension.
18 Oct 2022
Telmisartan does not improve walking performance in PAD
A randomized double-blind trial compared the angiotensin-receptor blocker with placebo in patients with peripheral artery disease (PAD) and found no difference in six-minute walk distance over six months.
11 Oct 2022
Latest updates on ACP's priorities, initiatives
ACP Spotlight offers readers a look at ACP's current top priorities and initiatives, as well as highlights from our e-newsletter, ACP Internist Weekly.
1 Jan 2022
Palliative care's place outside cancer
Integrated palliative care is important in offering comfort measures to patients with conditions that are expected to shorten their life spans.
1 Jun 2019
New guidance urges caution on testosterone
Internists considering testosterone therapy are ideally positioned to consider a broader differential diagnosis that will actually help the patient.
1 May 2020